Search results
Showing 4001 to 4050 of 4138 results for patient
NICE guidance addresses the best approach to the diagnosis and management of ME/CFS
NICE has today (10 November 2020) published its draft guideline on the diagnosis and management of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
How NICE manages the potential conflicts of interests of patient experts
People with lived experience provide valuable insight into the impact of NICE’s’ guidance and advice.
This International Women’s Day, we’re focusing on the invaluable contributions of 2 of the women who help shape our guidance through their independent voluntary committee roles. They talk to us about their involvement with NICE and what #InspireInclusion means to them.
Over 500 people a year can access a new life extending lung cancer treatment
An innovative life-extending drug for treating mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults is being recommended by NICE as an option for use within the Cancer Drugs Fund.
NHS Talking Therapies for anxiety and depression services saw record referrals in 2023/24.
Benefits of new Alzheimer's treatment lecanemab are too small to justify the cost to the NHS
Our draft recommendation follows analysis of clinical trial evidence and reviewing the benefits of slowing disease progression, with the cost of treatment.
Two new treatment options for incurable blood cancer assessed
We’ve recommended 2 new treatments for multiple myeloma, an incurable blood cancer that affects bone marrow, in draft guidance issued for public consultation.
How NICE is ensuring its topic prioritisation decisions are grounded in lived experience
Simon Denegri discusses NICE’s commitment to involving the public voice in its work and decisions.
More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.
More than 700 people set to benefit from new treatment option for advanced lymphoma.
Colorectal cancer patients with rare mutations to benefit from life-extending treatment
NICE recommends pembrolizumab for colorectal cancer patients with rare mutations.
Shared decision making recommendations will ensure people are at the heart of healthcare
NICE’s new guideline on shared decision making will help transform people’s experiences of health and social care.
NICE recommends innovative technology for people with breast cancer
A magnetic marker liquid injected into people with invasive breast cancer will help surgeons discover if the cancer has spread.
Children with a rare, fatal, genetic disorder will be able to benefit from a new one-off treatment under new NICE guidance.
Following the successful evaluation of Zio XT, developers of digital health technologies are encouraged to engage with NICE through one of several different routes.
People in England could benefit from new endometrial cancer treatment
Innovative new drug for treating endometrial cancer in adults recommended by NICE as an option for use within the Cancer Drugs Fund.
How my experience as a patient helped shape NICE guidelines for colorectal cancer
Following my surgery and treatment for colorectal cancer in 2014, I wanted to contribute to research in the cancer field and hopefully improve things for patients in the future.
NICE has recommended a new option for people with difficult-to-treat multiple myeloma
Around 5,700 cases of multiple myeloma are diagnosed each year in the UK. NICE has recommended a new option for people with difficult-to-treat multiple myeloma.
This indicator covers the percentage of patients aged between 25 and 84 years with a new diagnosis of hypertension or type 2 diabetes, recorded in the preceding 12 months (excluding those with pre-existing cardiovascular disease, chronic kidney disease, familial hypercholesterolaemia or type 1 diabetes) who have had a consultation for full formal cardiovascular disease risk assessment between 3 months before or 3 months after date of diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM132
This indicator covers the percentage of patients aged 50 to 90 years with rheumatoid arthritis who have had an assessment of fracture risk using a risk assessment tool adjusted for RA in the preceding 27 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM57
NICE’s methods and processes for evaluating new treatments for use in the NHS are appropriate for the new class of Alzheimer’s drugs but key issues need to be considered, a new report has found.
Learn more about NICE's new guideline on identifying and managing adrenal insufficiency
Hospital, to discuss the guideline and the benefits it will provide to patients and healthcare professionals. Other ways to listen Our...
Find out about the role of NICE's independent advisory committees
flexibility they have in deciding what medicines should be made available to NHS patients in England. Our guests are NICE's director of...
NICE recommends better targeting of antibiotics for suspected sepsis
Our guidance recommends better targeting of antibiotics to those at the highest risk of suspected sepsis to ensure the right people receive treatment.
New treatment for cardiovascular disease could benefit millions
Up to 2.1 million people with cardiovascular disease (CVD) could benefit from a new cholesterol target outlined in NICE guidance for the first time.
KardiaMobile recommended for people having antipsychotic medication
NICE publishes first draft guidance from its Early Value Assessment pilot project recommending smartphone-linked ECG device
Around 105,000 people with type 1 diabetes could benefit from NICE’s draft recommendation
Around 1,500 people aged 12 years and over with melanoma are set to benefit from pembrolizumab, a drug that reduces the chance of it returning.
NICE approves routine use of drug combination for advanced breast cancer
A life-extending drug combination for some people with advanced breast cancer will now be available for routine use in the NHS.
NICE welcomes Dr Michael Borowitz as new NICE non-executive director
New NICE non-executive director appointment approved by the Secretary of State for Health and Social Care
NICE conditionally recommends 5 promising technologies for Parkinson's disease
These promising technologies could help improve symptoms and quality of life for people with Parkinson’s disease.
Routine funding recommended for Duchenne muscular dystrophy gene therapy ataluren
NICE has today published final guidance which recommends ataluren (also called Translarna and made by PTC Therapeutics) for treating Duchenne muscular dystrophy (DMD) caused by a nonsense mutation.
NICE recommends new diagnostic devices for men with suspected prostate cancer in draft guidance
Four new diagnostic devices for men with suspected prostate cancer, which reduce the chances of biopsy related sepsis, have been recommended for use by NICE.
Thousands of people living with obesity are set to benefit from a new drug which has helped those using it to reduce their weight by more than 10 per cent.
Hundreds of people with a rare blood disorder have access to a new treatment regimen following draft guidance from NICE.
NICE recommends range of treatments for people with chronic primary pain
People with chronic primary pain should be offered a range of treatments to help them manage their condition.
Change in treatment for people with early breast cancer to benefit around 4,000
Around 4,000 people are set to benefit from a change in treatment for early breast cancer following provisional approval by NICE of abemaciclib in combination with hormone therapy.
New guidance recommends transplant with good bacteria taken from poo
Up to 500 people each year could be treated using faecal microbiota transplant for multiple recurrences of Clostridium difficile infections.
NICE recommends novel treatment for debilitating inherited skin condition
Around 670 people in England with skin wounds caused by a rare inherited disorder to benefit from a new treatment to help the healing process.
Artificial intelligence to speed up contouring in radiotherapy treatment planning
Nine artificial intelligence technologies can be used to help plan the treatment of those undergoing external beam radiotherapy for cancers
NICE launches refreshed support service for life sciences industry
NICE has launched its refreshed support service for the life sciences sector, NICE Advice.
NICE launches first modular update to its methods and processes
NICE’s methods and processes now include a proportionate approach to technology appraisals, and a new way of updating recommendations on COVID-19 treatments.
NICE recommended treatment for Parkinson's set to benefit hundreds
Around 900 adults with advanced Parkinson’s are set to benefit from new treatment foslevodopa–foscarbidopa after NICE approved it for NHS use in final draft guidance published today (26 October 2023).
More than 400 people could benefit from life-extending advanced lung cancer treatment
Durvalumab recommended as an option for treating non-small-cell lung cancer.
Innovative technology to detect abnormal heart rhythms recommended by NICE
Zio XT is the first assessment, via the NICE digital health technologies guidance development pilot project, to be recommended for NHS use.
Dr Patterson, a GP working on the frontline of primary care, describes why he is encouraged by NICE's approval of tirzepatide (Mounjaro).
A safe space for bold ideas – implementing a sandbox approach in health technology assessment
Colleagues in our Science Policy and Research Programme discuss their international research, paving the way for next generation health technology assessment.
Introducing CHEERS-AI: improving health economic evaluation reporting for AI technologies
Our contribution to world-leading research.
Your voice is needed – my experience as a NICE committee member
Dr Raja discusses the vital role frontline NHS colleagues have on our independent committees, and how you can get involved.
NICE provides access to new treatment option for advanced breast cancer
NICE has today (20 April 2021) published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF).